evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

12 questions · 15 findings · 8 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 5 · 33.3%GRADE not reported 0 · 0%Very low 3 · 20%Low 3 · 20%Moderate 4 · 26.7%High 0 · 0%

Low molecular weight heparin and idraparinux vs usual care

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

2 findings from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs active control

Major bleeding · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Low molecular weight heparin vs no prophylaxis

All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review